Martingale Asset Management L P grew its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) by 75.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,783 shares of the company’s stock after buying an additional 14,946 shares during the quarter. Martingale Asset Management L P owned 0.06% of Harmony Biosciences worth $1,391,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. nVerses Capital LLC purchased a new stake in shares of Harmony Biosciences during the 2nd quarter valued at about $36,000. CWM LLC raised its position in shares of Harmony Biosciences by 111.7% during the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after buying an additional 775 shares in the last quarter. Quarry LP purchased a new stake in shares of Harmony Biosciences during the 2nd quarter valued at about $62,000. Quantbot Technologies LP purchased a new stake in shares of Harmony Biosciences during the 3rd quarter valued at about $74,000. Finally, Headlands Technologies LLC raised its position in shares of Harmony Biosciences by 1,608.1% during the 2nd quarter. Headlands Technologies LLC now owns 2,545 shares of the company’s stock valued at $77,000 after buying an additional 2,396 shares in the last quarter. 86.23% of the stock is currently owned by hedge funds and other institutional investors.
Harmony Biosciences Price Performance
Shares of HRMY stock opened at $34.67 on Monday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The company has a market capitalization of $1.98 billion, a P/E ratio of 16.43, a P/E/G ratio of 0.64 and a beta of 0.77. The company’s 50-day simple moving average is $35.16 and its two-hundred day simple moving average is $33.75. Harmony Biosciences Holdings, Inc. has a one year low of $28.14 and a one year high of $41.61.
Insider Activity
In other news, insider Jeffrey Dierks sold 21,496 shares of the stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total transaction of $869,943.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 30.80% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on the stock. Needham & Company LLC restated a “buy” rating and set a $52.00 target price on shares of Harmony Biosciences in a research report on Tuesday, October 29th. Oppenheimer reissued an “outperform” rating and issued a $59.00 price objective (up from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Mizuho increased their price objective on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, October 10th. Cantor Fitzgerald increased their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Finally, UBS Group began coverage on shares of Harmony Biosciences in a research report on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $47.00.
Check Out Our Latest Stock Analysis on Harmony Biosciences
Harmony Biosciences Company Profile
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Featured Stories
- Five stocks we like better than Harmony Biosciences
- 5 discounted opportunities for dividend growth investors
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- How to Calculate Options Profits
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- Most Volatile Stocks, What Investors Need to Know
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.